{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:46:19Z","timestamp":1792176379549,"version":"4.4.0"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41433-026-04792-8","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T16:00:13Z","timestamp":1786204813000},"page":"2311-2312","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the mixed marketing authorisation pathway: a case study in ophthalmology"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6685-4402","authenticated-orcid":false,"given":"Luke","family":"Nicholson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6769-2967","authenticated-orcid":false,"given":"Deepali","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"4792_CR1","doi-asserted-by":"crossref","unstructured":"European Medicines Agency guideline on similar biological medicinal products: a further step for a safe use of biosimilars. 2015;13:3.","DOI":"10.1186\/s12948-015-0010-3"},{"key":"4792_CR2","unstructured":"Directive 2001\/83\/EC of the European Parliament and of the Council. Accessed July 6th, 2026 https:\/\/eur-lex.europa.eu\/eli\/dir\/2001\/83\/oj\/eng."},{"key":"4792_CR3","unstructured":"Outlook Therapeutics. Bevacizumab gamma EPAR Summary. EMA. Accessed July 6th, 2026 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lytenava."},{"key":"4792_CR4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) in the treatment of neovascular age-related macular degeneration. Ophthalmology. 2006;113:363\u201372.","journal-title":"Ophthalmology"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04792-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04792-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04792-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:55:42Z","timestamp":1792173342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04792-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":4,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4792"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04792-8","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LN has received speaker fees from Alimera, AbbVie, Advanz, Bayer, Roche. LN has been on advisory boards for Astellas, Bayer, Roche, Outlook Therapeutics. LN has received conference and Travel support from Roche. LN has received institutional research funding from Optos and Bayer.\u00a0DV has received speaker fees from Alimera, AbbVie, Bayer, and Roche. AV has been on Advisory boards or received other financial remuneration from AbbVie, Astellas, Bayer, Roche, Sandoz, Teva, Outlook Therapeutics. DV has received conference and travel support from Roche, Bayer, AbbVie. DV has received institutional research funding from Alimera sciences, AbbVie, Boehringer Ingelheim Pharmaceuticals.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}